Send to printer »

Insight & Intelligence™ : Dec 16, 2013

Top 10 Highest-Paid CEOs of Diagnostics Companies

In most cases, compensation for company leaders is growing as the potential of Dx are realized.

We live in an era where it's possible to diagnose a disease long before the symptoms begin to appear, and Dx companies are at the forefront of this frontier. While the potential is great, some might wonder what profit there is in the field right now. Well, here's a list that may help clarify that.

Below is a list of 10 CEOs of publicly traded companies focused on diagnostics, as opposed to drug discovery or tools/tech, as ranked by their total 2012 compensation as disclosed in proxy reports (Form DEF 14As filed by U.S.-based companies), Form 20-Fs (filed by overseas-based companies), and S-1 registration statements (filed by newly public companies).

Each listing includes the names, titles, and companies of each listed CEO; their compensation for 2012 and 2011, recorded as calendar years unless noted otherwise; the percentage change between 2011–2012 compensation; and footnotes that explain wide discrepancies in compensation or other information.

A few observations from the results: Diagnostics CEOs generally don’t get paid as much as their drug discovery and tools/tech counterparts, more than likely because the companies are younger than legacy pharmas, biotech giants, and tools/tech developers. None of the diagnostics CEOs were paid above $6 million, compared to seven tools/tech CEOs, not to mention the eight-figure compensation packages routine for biopharma leaders. However, the top 10 were all compensated above $1 million, followed by another handful of diagnostics CEOs not appearing on this list, who were paid in the high six figures—and who are likely to reach the million-dollar level as their companies continue to grow. Two women appear among the top 10 compensated diagnostics CEOs, compared to zero in the biopharma and tools/tech lists.

#10. Larry Mehren

Company: Accelerate Diagnostics (formerly Accelr8 Technology)

Title: President, CEO, and CFO

2012 Compensation: $1,152,0461

2011 Compensation: N/A

% Change: N/A

#9. Gail S. Page

Company: Vermillion

Title: Director, President, and CEO (2005–2009; 2010–2012)2

2012 Compensation: $1,289,4932

2011 Compensation: $1,627,703

% Change: -20.8%

#8. Hany Massarany

Company: GenMark Diagnostics

Title: President, CEO and Director

2012 Compensation: $1,349,6013

2011 Compensation: $2,028,306

% Change: -33.5%

#7. Geert Walther Nygaard4

Company: Epigenomics

Title: CEO (2007–2012)4

2012 Compensation: €872,500 ($1,181,494.13)4,5,6

2011 Compensation: €390,000 ($528,035.23)4,6

% Change: 123.7%

#6. Kimberly J. Popovits

Company: Genomic Health

Title: President and CEO

2012 Compensation: $2,144,086

2011 Compensation: $1,833,605

% Change: 16.9%

#5. Kevin Conroy

Company: Exact Sciences

Title: President, CEO, and Director

2012 Compensation: $2,707,615

2011 Compensation: $1,322,413

% Change: 104.7%

#4. Eric Bouvier

Company: BG Medicine

Title: President and CEO

2012 Compensation: $2,756,7757

2011 Compensation: N/A7

% Change: N/A

#3. Ron Zwanziger

Company: Alere

Title: Chairman of the Board, CEO, and President

2012 Compensation: $3,841,0808

2011 Compensation: $900,713

% Change: 326.4%8

#2. Robert A. Cascella

Company: Hologic

Title: President and CEO

2012 Compensation: $5,387,104

2011 Compensation: $6,038,2999

% Change: -10.8%

#1. Peter D. Meldrum

Company: Myriad Genetics

Title: President and CEO

Year Ending June 30, 2012 Compensation: $5,951,70810

Year Ending June 30, 2011 Compensation: $4,866,58410

% Change: 22.3%